GGrantIndex
← Search

Cancer Biology and Biochemistry (02)

$3,608P30FY2018CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications, trials & patents

Trial NCT07614022Trial NCT07324577Trial NCT07322367Trial NCT07282444Trial NCT07203534Trial NCT07196241Trial NCT07175376Trial NCT07119489Trial NCT07046936Trial NCT06945042Trial NCT06709404Trial NCT06654245Trial NCT06480591Trial NCT06441266Trial NCT06340503Trial NCT05984680Trial NCT05934851Trial NCT05877404Trial NCT05854966Trial NCT05825066Trial NCT05796518Trial NCT05696782Trial NCT05692635Trial NCT05597878Trial NCT05395936Trial NCT05309655Trial NCT05242770Trial NCT05212272Trial NCT05204290Trial NCT05030038Trial NCT04897217Trial NCT04858269Trial NCT04797884Trial NCT04677816Trial NCT04659993Trial NCT04623515Trial NCT04586127Trial NCT04526080Trial NCT04495751Trial NCT04485026Trial NCT04454489Trial NCT04430335Trial NCT04415944Trial NCT04375384Trial NCT04337580Trial NCT04327700Trial NCT04266470Trial NCT04253964Trial NCT04217317Trial NCT04174742Trial NCT04173247Trial NCT04111107Trial NCT04040244Trial NCT04037527Trial NCT03998189Trial NCT03987568Trial NCT03987555Trial NCT03982537Trial NCT03963739Trial NCT03958747Trial NCT03929211Trial NCT03890614Trial NCT03880526Trial NCT03874065Trial NCT03870529Trial NCT03870451Trial NCT03868943Trial NCT03867175Trial NCT03861091Trial NCT03861065Trial NCT03796273Trial NCT03746262Trial NCT03741868Trial NCT03741829Trial NCT03740035Trial NCT03681405Trial NCT03662074Trial NCT03529565Trial NCT03520283Trial NCT03505762Trial NCT03505736Trial NCT03505671Trial NCT03379376Trial NCT03374995Trial NCT03370159Trial NCT03188432Trial NCT03152786Trial NCT03148080Trial NCT03139435Trial NCT03122743Trial NCT03087591Trial NCT03032250Trial NCT02971410Trial NCT02971397Trial NCT02949843Trial NCT02835222Trial NCT02835066Trial NCT02832154Trial NCT02827838Trial NCT02747407

Abstract

CANCER BIOLOGY AND BIOCHEMISTRY PROGRAM Project Summary The Cancer Biology and Biochemistry Program (CBB) is a continuation of the former Cellular Damage and Defense Program that earned an ?outstanding? rating during the last CCSG renewal. During the most recent funding period, the overall scientific theme of the Program further coalesced around cancer biology and biochemistry, with three established themes clearly delineated: Redox Modulation, Genomic Integrity, and Cellular Metabolism. These themes have been strengthened through faculty development and recruitment, consistent with the evolution and growth of the Program. Importantly, the themes are designed to meet the scientific needs of the catchment area. As noted in the Director's Overview and the Cancer Prevention and Control Program, smoking is highly prevalent in the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) catchment population. Tobacco smoke is well-known to induce reactive oxygen species and DNA damage in cells. Moreover, reactive oxygen species induce DNA damage, and both reactive oxygen species and DNA damage result in aberrant cellular metabolism. These processes are intimately involved in other cancer-related processes driven by oncogenes, therapeutic response, radiation response, and inflammation, to name a few. The cancer research landscape reflects the interconnection among the pathways involved in these processes. As a result, there has been targeted recruitment of investigators who engage in these three themes and bring expertise that promotes expansion and evolution of the science. The Program and WFBCCC leadership, in concert with WFBCCC External Advisory Board, decided that a name change was appropriate to more easily define and encompass the scientific activities of the Program investigators. Importantly, the name accurately reflects the overall scientific expertise of the Program members, the major departmental affiliations within the institution, and the continued thematic development by the Program leadership. The goals of the Program are to understand how biochemistry shapes cancer cell origin and to translate these findings towards human interventions, in collaboration with the Clinical Research Program. The goals of the Program are achieved through the following Specific Aims to: 1) Determine how specific biochemical pathways affect tumor initiation and development; and 2) Develop novel therapeutic strategies to improve cancer therapy. The CBB Program is composed of 28 members from 13 departments or sections. Program members have $3.1M in extramural funding of which 57.9% is from the NCI (excludes $.7M training). Among the 240 publications by CBB Program members, 29% were intra-programmatic, 22% were inter-programmatic, and 59% were inter- institutional. A robust translational thrust is indicated by having 6 members serve as co-investigators on 11 clinical trials and 40 patent applications filed for various therapeutic, imaging, and diagnostic methodologies.

View original record on NIH RePORTER →